Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin for Neuroprotection in Perinatal Asphyxia
NCT02071160Phase 2Completed
- Sponsor
- Tanta University
- Start
- Jan 2012
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of melatonin in hypoxic-ischemic encephalopathy (HIE) (3 arms), sponsored by Tanta University. Primary endpoints: Serum melatonin concentration at 5 days, Plasma superoxide dismutase activity at 5 days and 1 more. Started Jan 2012; status: completed.
02
Drugs
melatonin
03
Conditions
hypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on NCT02071160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02071160.